NMRA
Neumora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.48
+1.86%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.47
From 52W high−86.56%
Volume1.50M
Market cap$90.68M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.47
From 52W high
−86.56%
Volume
1.50M
Market cap
$90.68M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
33.6
MomentumView details →
1D Return
+1.86%
YTD Return
−72.95%
SummaryUpdated Jun 1, 2026
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Watertown, Massachusetts. The company went public in September 2023 and focuses on developing novel therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Originally incorporated as RBNC Therapeutics, Inc., the company changed its name to Neumora Therapeutics in October 2021. Neumora is currently advancing multiple clinical-stage programs targeting conditions that affect approximately 1.5 billion people worldwide, with its lead program being navacaprant for major depressive disorder.
Similar companies
Latest newsMore news →
Paul L. Berns stepped down as Executive Chairperson of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.67d agoDoron Sagman, M.D., FRCPC was appointed Chief Medical Officer of Neumora Therapeutics, Inc., effective August 14, 2026.67d agoJoshua Pinto, Ph.D. was promoted to Chief Executive Officer and President, and Class III director of the Board of Directors of Neumora Therapeutics, Inc., effective August 14, 2026.67d ago